ALK and non-small cell lung carcinoma: A recent randomized, multicentre, open‐label, phase III study (NCT01828099) compared ceritinib and chemotherapy in stage IIIB/IV ALK‐rearranged NSCLC patients, which showed that ceritinib treatment significantly prolongs PFS.